Peter E Schwartz MD

John Slade Ely Professor of Obstetrics, Gynecology, and Reproductive Sciences; Vice Chair, Gynecology; Section Chief, Gynecologic Oncology

Clinical Interests

Ovarian, uterine, vaginal, cervical and vulvar cancer; Difficult gynecologic surgery; Screening for ovarian cancer; Gestational neoplasia; Brachytherapy


Board Certifications

1979
Gynecologic Oncology, Board Certified
1973
Obstetrics & Gynecology, Board Certified

Patient Care Locations

peter_schwartzfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
An open label Phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of the anti-mesothelin antibody drug conjugate BAY 94-9343 in subjects with advanced solid tumors
Other Female GenitalA Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Detection of Sentinel Lymph Nodes in Patients with Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes with Fluorescence Imaging

More Clinical Trials...

Edit Profile